TOKYO, Mar 17 (Pulse News Wire) – RIBOMIC Inc. (4591.T) resolved to adjust the funding purposes for its 18th through 20th tranches of rights issues with exercise price adjustment clauses, disclosed during a board meeting held today.
Originally intended for clinical development costs related to RBM-007 for achondroplasia and operational funds, the revised plan now includes development expenses for RBM-007 covering clinical trials and non-clinical tests necessary for regulatory approval. Specifically, the changes involve shifting focus towards Phase III clinical trials and aligning non-clinical test data acquisition with the application process for regulatory approval. This strategic shift aims to streamline the approval process and enhance overall project reliability.
As such, the total allocated amount remains unchanged but the purpose of the funds has been reallocated to support these updated objectives. The adjustments do not impact the fiscal year ending March 2026 performance metrics. Details of the revised allocation are as follows: | Specific Purpose | Allocated Amount | Expenditure Period | |-----------------|------------------|-------------------| | Development Costs for RBM-007 | [NUM_3] | April 2026 - March 2029 | | Operational Funds | 876 million yen | April 2026 - March 2029 | Total allocated amount remains [NUM_4] million yen.
🟢 Confidence: High AI-translated content.